Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations
Author:
Affiliation:
1. Honor Health Pulmonary Hypertension ClinicHonorHealthPhoenixAZUSA
2. University of ArizonaTucsonAZUSA
3. University of Colorado HealthAuroraCOUSA
Funder
Actelion Pharmaceuticals
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1177/2045894020931324
Reference13 articles.
1. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT);Galiè N;Eur Heart J,2016
2. Pulmonary arterial hypertension: tailoring treatment to risk in the current era;Gaine S;Eur Respir Rev,2017
3. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension;Kingman M;Pul Circ,2017
4. A systematic review of transition studies of pulmonary arterial hypertension specific medications;Sofer A;Pulm Circ,2017
5. Right ventricular afterload predicts long‐term transition from parenteral to oral treprostinil in pulmonary arterial hypertension;Maestas T;Pulm Circ,2018
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Management of Pulmonary Arterial Hypertension;Seminars in Respiratory and Critical Care Medicine;2023-06-27
2. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report;ESC Heart Failure;2023-06-19
3. Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration;Frontiers in Pediatrics;2023-03-08
4. Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension;Respiratory Medicine Case Reports;2022
5. TRANSITIONING FROM PARENTERAL PROSTACYCLIN THERAPY TO ORAL SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION;Chest;2021-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3